ScoreWhy is BridgeBio Pharma, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -27.00% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.52
2
Flat results in Jun 25
- NET PROFIT(HY) At USD -332.29 MM has Grown at -338.44%
- INTEREST(HY) At USD 79.78 MM has Grown at 71.91%
- OPERATING CASH FLOW(Y) Lowest at USD -655.82 MM
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 159.76%, its profits have fallen by -22.5%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -3.12% over the previous quarter and currently hold 13.49% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is BridgeBio Pharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
BridgeBio Pharma, Inc.
181.26%
2.99
51.35%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
42.20%
EBIT Growth (5y)
-27.00%
EBIT to Interest (avg)
-8.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.59
EV to EBIT
-13.70
EV to EBITDA
-13.82
EV to Capital Employed
57.44
EV to Sales
73.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-419.24%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
NET SALES(Q)
At USD 110.56 MM has Grown at 247.1%
NET PROFIT(HY)
Higher at USD -332.29 MM
RAW MATERIAL COST(Y)
Fallen by -652.09% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -107.38 %
INVENTORY TURNOVER RATIO(HY)
Highest at 1.34 times
-16What is not working for the Company
NET PROFIT(HY)
At USD -332.29 MM has Grown at -338.44%
INTEREST(HY)
At USD 79.78 MM has Grown at 71.91%
OPERATING CASH FLOW(Y)
Lowest at USD -655.82 MM
Here's what is working for BridgeBio Pharma, Inc.
Net Sales
At USD 110.56 MM has Grown at 247.1%
over average net sales of the previous four periods of USD 31.85 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Profit
Higher at USD -332.29 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -107.38 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 1.34 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -652.09% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for BridgeBio Pharma, Inc.
Net Profit
At USD -332.29 MM has Grown at -338.44%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Interest
At USD 79.78 MM has Grown at 71.91%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Cash Flow
Lowest at USD -655.82 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
